Table 3 Anti-hypertensive medications, stratified by pre-existing hypertension

From: The impact of pre-existing hypertension and its treatment on outcomes in patients admitted to hospital with COVID-19

  

Pre-existing hypertension

 

Characteristic

Overall, N = 9197

No, N = 4754 (51.7%)

Yes, N = 4443 (48.3%)

p value

Prescribed anti-hypertensive, Yes

4570 (49.7%)

985 (20.7%)

3,585 (80.7%)

<0.001

Number of anti-hypertensives

   

<0.001

 0

4627 (50.3%)

3769 (79.3%)

858 (19.3%)

 

 1

1988 (21.6%)

569 (12.0%)

1419 (31.9%)

 

 2

1666 (18.1%)

313 (6.6%)

1353 (30.5%)

 

 3 or more

916 (10.0%)

103 (2.2%)

813 (18.3%)

 

ACEi or ARB

2499 (27.2%)

403 (8.5%)

2096 (47.2%)

<0.001

Beta-blocker

2391 (26.0%)

571 (12.0%)

1820 (41.0%)

<0.001

Diuretic

1806 (19.6%)

363 (7.6%)

1443 (32.5%)

<0.001

CCB

1498 (16.3%)

174 (3.7%)

1324 (29.8%)

<0.001

ACEi

1512 (16.4%)

286 (6.0%)

1226 (27.6%)

<0.001

ARB

1007 (10.9%)

118 (2.5%)

889 (20.0%)

<0.001

  1. p value is for comparison between pre-existing hypertension and no pre-existing hypertension documented, using Chi-squared test
  2. ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, BB beta-blocker, CCB calcium channel blocker, D diuretic. ACEi or ARB is a pooled variable and distinct from ACEi and ARB
Back to article page